6 times/cycle). If the patients want to continue the vaccination after completion of the first cycle of 6 vaccinations, the peptide vaccination will be allowed to continue .
Sponsors
Kurume University Cancer Vaccine Center
Conditions
endocrine malignant tumorsesophageal cancerhead and neck cancerhematological malignancyskin cancer
Phase 2
Phase II clinical trial of personalized peptide vaccination for patient with advanced esophageal cancer resistant to standard therapies .
Active, not recruitingJPRN-UMIN000008824
Start: 2012-09-01Target: 50Updated: 2026-06-29
Phase II clinical trial of personalized peptide vaccination for patient with advanced skin cancer resistant to standard therapies .
Active, not recruitingJPRN-UMIN000008828
Start: 2012-09-01Target: 50Updated: 2026-06-29
Phase II clinical trial of personalized peptide vaccination for patient with advanced head and neck cancer resistant to standard therapies .
Active, not recruitingJPRN-UMIN000008825
Start: 2012-08-23Target: 50Updated: 2026-06-29
Phase II clinical trial of personalized peptide vaccination for patient with advanced endocrine malignant tumors resistant to standard therapies .
Active, not recruitingJPRN-UMIN000008826
Start: 2012-09-01Target: 50Updated: 2026-06-29
Phase II clinical trial of personalized peptide vaccination for patient with advanced hematological malignancy resistant to standard therapies .
Active, not recruitingJPRN-UMIN000008823
Start: 2012-09-01Target: 50Updated: 2026-06-29